Evidence map›Paper›PMID 21921725›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2011

HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients.

Nadeera Sidique, Anita Kohli, Bhavana Shivakumar, Stephen Migueles, G Mani Subramanian, Susanna Naggie, Michael A Polis, Henry Masur, Shyam Kottilil

Registry-linked trialAbstract readComparative StudyLetter
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00018031 (A Non-Randomized, Open Label, Study to Assess Hepatitis C Viral Kinetics in Predicting the Clinical Response in Patients With Hepatitis C Infection Coinfected With HIV-1 Treated With Peginterferon Alpha-2b and Ribavirin), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00018031 phase2completednot on this map

A Non-Randomized, Open Label, Study to Assess Hepatitis C Viral Kinetics in Predicting the Clinical Response in Patients With Hepatitis C Infection Coinfected With HIV-1 Treated With Peginterferon Alpha-2b and Ribavirin

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2001 to 2009Enrolled36ConditionsHepatitis C, HIV InfectionsArmsPeginterferon alfa-2b, Ribavirin
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nadeera Sidique
Anita Kohli
Bhavana Shivakumar
Stephen Migueles
G Mani Subramanian
Susanna Naggie
Michael A Polis
Henry Masur
Shyam Kottilil

Funding

Therapeutic Strategies for the Management of HCV/HIV co- infectionZIAAI000390 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI FAUCI, ANTHONY S. · 2009 to 2014
$4.2M
Moving Towards More Individualized Therapies in HIV/HCV Co-infected PatientsK23AI096913 · NIAID · DUKE UNIVERSITY · PI NAGGIE, SUSANNA · 2011 to 2014
$355k
DC Partnership for HIV/AIDS Progress (DC PFAP)ZIACL009010 · CLC · CLINICAL CENTER · PI MASUR, HENRY · 2010 to 2025
$0k
Intramural NIH HHS Z99 AI999999NIAID NIH HHS K23 AI096913NIAID NIH HHS Y99 AI999999
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAnti-HIV AgentsAntiviral AgentsDrug Therapy, CombinationFemaleHepacivirusHepatitis C, ChronicHIVHIV InfectionsHumansInterferon-alphaInterferon alpha-2MaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsAnti-HIV AgentsAntiviral AgentsInterferon-alphaInterferon alpha-2peginterferon alfa-2apeginterferon alfa-2bPolyethylene GlycolsRecombinant ProteinsRibavirin

Identifiers

PMID21921725
PMCPMC3175052

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.